Daptomycin Evidence Guide
Daptomycin (Cubicin) is FDA-approved for serious gram-positive infections including MRSA bacteremia, endocarditis, and complicated skin infections. It is a first-line IV antibiotic with extensive Phase 3 data and a 20+ year clinical track record. For researchers studying gram-positive infection treatment, daptomycin is a validated standard-of-care option with high-quality evidence.
Our Take
Daptomycin (Cubicin) is FDA-approved for serious gram-positive infections including MRSA bacteremia, endocarditis, and complicated skin infections. It is a first-line IV antibiotic with extensive Phase 3 data and a 20+ year clinical track record. For researchers studying gram-positive infection treatment, daptomycin is a validated standard-of-care option with high-quality evidence.
- Best for
- MRSA bacteremia, right-sided endocarditis, complicated skin and soft tissue infections, gram-positive infection treatment
- Evidence grade
- Level A
- Confidence
- High
- Starting point
- 4mg/kg IV daily (skin infections); 6mg/kg IV daily (bacteremia/endocarditis)
Benefits and Evidence
- MRSA Bacteremia Treatment: Level A, includes human evidence - Phase 3 trials and extensive clinical experience demonstrate non-inferiority to vancomycin for S. aureus bacteremia and right-sided endocarditis, with potentially faster bactericidal activity.
- Complicated Skin Infections: Level A, includes human evidence - FDA-approved indication with robust evidence from large RCTs showing high cure rates (>80%) for complicated skin and soft tissue infections caused by gram-positive organisms.
- CPK Elevation (Adverse): Level A, includes human evidence - Creatine phosphokinase elevation is a recognized adverse effect occurring in 2-7% of patients, occasionally progressing to rhabdomyolysis. Weekly CPK monitoring is recommended.
Side Effects and Warnings
- CPK elevation and myopathy
- Diarrhea
- Headache
- Insomnia
- Nausea and vomiting
- Eosinophilic pneumonia (rare)
- Peripheral neuropathy (rare)
- Do NOT use for pneumonia (inactivated by pulmonary surfactant)
Research Dosage References
- <strong>Intravenous</strong> - 4 mg/kg - Once daily - FDA-approved dose for complicated skin and skin structure infections. Infused over 30 minutes or as 2-minute IV push.
- <strong>Intravenous</strong> - 6 mg/kg - Once daily - FDA-approved dose for S. aureus bacteremia and right-sided endocarditis. Higher doses (8-12 mg/kg) used off-label for refractory infections.
- <strong>Intravenous</strong> - 8-12 mg/kg - Once daily - Off-label high-dose regimen for difficult-to-treat infections. Requires close CPK monitoring.
Mechanism of Action
Daptomycin exerts rapid bactericidal activity through: 1. Calcium-dependent membrane insertion: In the presence of calcium ions, the lipophilic tail of daptomycin inserts into the gram-positive bacterial cell membrane. 2. Oligomerization and pore formation: Multiple daptomycin molecules aggregate within the membrane, forming ion-conducting channels. 3. Membrane depolarization: Rapid efflux of potassium ions leads to loss of membrane potential, cessation of DNA, RNA, and protein synthesis. 4. Rapid bactericidal action: Cell death occurs within hours without cell lysis, reducing endotoxin release compared to cell wall-active agents.
Legal Status
FDA-approved since 2003 (Cubicin). Prescription required. Available generically. Approved worldwide for complicated skin infections and S. aureus bacteremia. On the WHO Essential Medicines List.
Primary Sources
- Daptomycin versus standard therapy for bacteremia and endocarditis caused by S. aureus. N Engl J Med, 2006.
- Daptomycin for complicated skin and skin-structure infections. Clin Infect Dis, 2004.
- Mechanism of action of daptomycin. Proc Natl Acad Sci U S A, 2012.